The goal of this grant application is to isolate and clone the sulfatases of heparin-like glycosaminoglycans. More specifically, during the phase I part of the grant application, the investigators will focus on the 2-O sulfatase as a model enzyme, which will enable the isolation of other sulfatases during Phase II.
The specific aims of this phase I project are: 1) to isolate and purify the 2-O sulfatase from Flavobacterium heparinum, and 2) clone and recombinantly express 2-O sulfatase in E. coli. The cloning of the sulfatases is expected to a) provide a methodology that will facilitate the isolation of the other heparin-like GAG sulfatases (i.e. 3-O, 6-) and the NS degrading enzymes), b) enable the development of an integrated enzyme based approach towards heparin-like GAG structure-function investigation and sequencing, and c) enable the commercial availability of the sulfatases for applications beyond heparin-like GAG sequencing, such as in the clinic.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK055922-01
Application #
2866865
Study Section
Special Emphasis Panel (ZRG1-SSS-2 (01))
Program Officer
Sato, Sheryl M
Project Start
1999-06-01
Project End
2000-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Matrix Engineering
Department
Type
DUNS #
City
Medford
State
MA
Country
United States
Zip Code
02155